PET/CT with 18F-BPA for various oncological diseases. The first experience of application in Russia
Authors:
- P. E. TulinPTP. E. Tulin
- A. A. LipengoltsALA. A. Lipengolts
- A. S. SubbotinASA. S. Subbotin
- A. V. FilimonovAFA. V. Filimonov
- V. V. SolomyanyVSV. V. Solomyany
- I. A. SkripachevISI. A. Skripachev
- D. I. NevzorovDND. I. Nevzorov
- I. V. SamoylenkoISI. V. Samoylenko
- B. I. DolgushinBDB. I. Dolgushin
- I. S. StilidiISI. S. Stilidi
Open Access
- 23 December 2025
- journal article
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (4) , 50-59
Abstract
Purpose : To determine the possibilities of PET/CT with 18 F-FBFA in the diagnostics of oncological diseases. Material and methods : This prospective study included 32 patients with various verified oncological diseases. All patients underwent two consecutive PET/CT studies with two 18 F-FDG and 18 F-BPA. Two parameters were measured for 18 F-BPA: 1) Accumulation in the primary tumor and/or in metastases / recurrent tumors; 2) The tumor to normal tissue ratio (TNR). Results : Data on the physiological accumulation of 18 F-BPA were obtained (the lowest values in the brain were SUV min-max 0.45–2.99 (median 1.42), the highest values were in the oral mucosa SUV min-max 2.24–8.81 (median 4.76). Foci of pathological accumulation of 18 F-BPA corresponding to tumor tissue were identified (the highest values of accumulation of 18 F-BPA were detected in multiple myeloma — SUV max 9.59, the lowest — in nasopharyngeal plasmocytoma — SUV max 4.42). The TNR calculation made it possible to divide patients into 2 groups: TNR ≥ 2,5 (n = 15), TNR < 2,5 (n = 6), determining the potential for BNCT. Conclusion : 18 F-BPA has potential as an independent diagnostic tool. 18 F-BPA deserves attention for study as an agent that allows for differential diagnosis between tumor and non-tumor changes. The further search for the possibilities of using PET/CT with 18 F-BPA on larger cohorts of patients with various oncological diseases planned.Keywords
This publication has 13 references indexed in Scilit:
- boron neutron capture therapy for glioblastoma: The delivery dilemmaLife Sciences, 2025
- Boron neutron capture therapy of cancer: where do we stand now?Cancer Communications, 2024
- Correcting for the heterogeneous boron distribution in a tumor for BNCT dose calculationScientific Reports, 2023
- 18F-FBPA PET in Sarcoidosis Comparison to Inflammation-Related Uptake on FDG PETClinical Nuclear Medicine, 2020
- Boron neutron capture therapy for malignant brain tumorsJournal of Neuro-Oncology, 2020
- Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survivalRadiotherapy and Oncology, 2019
- The role of PET/CT with 18F-fluorodeoxyglucose in detecting the progression of colorectal cancer in asymptomatic patients with elevated level of сarcinoembryonic antigen (literature review)Surgery and Oncology, 2019
- Correlation of 18F-BPA and 18F-FDG uptake in head and neck cancersRadiotherapy and Oncology, 2014
- Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancerRadiation Oncology, 2012
- Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-d,l-phenylalanine: A target compound for PET and boron neutron capture therapyInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1991